

## WEST Search History

[Hide Items](#)
[Restore](#)
[Clear](#)
[Cancel](#)

DATE: Sunday, April 02, 2006

<b>Hide?</b>	<b><u>Set Name</u></b>	<b><u>Query</u></b>	<b><u>Hit Count</u></b>
	<i>DB=PGPB,USPT,USOC; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L27	L25 and kringle	0
<input type="checkbox"/>	L26	L25 and kringle same (succinimidyl or maleimido)	0
<input type="checkbox"/>	L25	(514/19)[CCLS]	1753
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L24	0190970	25
<input type="checkbox"/>	L23	01090970	0
<input type="checkbox"/>	L22	2001090970	2
	<i>DB=USPT; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L21	6576610.pn.	1
	<i>DB=DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L20	9741824	2
<input type="checkbox"/>	L19	WO9741824	0
<input type="checkbox"/>	L18	199741824	0
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=OR</i>		
<input type="checkbox"/>	L17	wo009741824	0
<input type="checkbox"/>	L16	wo1997041824	0
<input type="checkbox"/>	L15	wo199741824	0
<input type="checkbox"/>	L14	97041824	1
<input type="checkbox"/>	L13	9041824	0
<input type="checkbox"/>	L12	wo97041824	0
<input type="checkbox"/>	L11	1997041824	0
<input type="checkbox"/>	L10	199741824	0
<input type="checkbox"/>	L9	wo 199741824	2487267
<input type="checkbox"/>	L8	L7 and kringle	2
<input type="checkbox"/>	L7	L6 and (succinimidyl or maleimido)	4
<input type="checkbox"/>	L6	davidson.in. and (succinimi\$ or maleimi\$)	18
<input type="checkbox"/>	L5	kringle.clm. and (succinimidyl or maleimido).clm.	0
<input type="checkbox"/>	L4	kringle same (succinimidyl or maleimido)	1
<input type="checkbox"/>	L3	kringle with (succinimidyl or maleimido)	1
<input type="checkbox"/>	L2	L1 and (succinimidyl or maleimido)	7
<input type="checkbox"/>	L1	(kringle with 5 with (protein or peptide)) with modif\$	8

END OF SEARCH HISTORY

FILE 'HOME' ENTERED AT 19:33:22 ON 02 APR 2006  
-> b caplus uspatfull uspat2 pctfull biosis scisearch medline  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY 0.42  
SESSION 0.42  
FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 19:34:20 ON 02 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 19:34:20 ON 02 APR 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 19:34:20 ON 02 APR 2006  
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 19:34:20 ON 02 APR 2006  
COPYRIGHT (C) 2006 Univentio

FILE 'BIOSIS' ENTERED AT 19:34:20 ON 02 APR 2006  
Copyright (C) 2006 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 19:34:20 ON 02 APR 2006  
Copyright (C) 2006 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 19:34:20 ON 02 APR 2006

-> s succinimidy1 and maleimid?

L1 11704 SUCCINIMIDYL AND MALEIMID?

L2 s 11 and (coupl? or conjug?)

L2 11039 L1 AND (COUPL? OR CONJUG?)

L3 s 12 and kringle

L3 405 L2 AND KRINGLE

-> dup remo l3

PROCESSING COMPLETED FOR L3

L4 377 DUP REMO L3 (28 DUPLICATES REMOVED)

-> s (succinimidy1 or maleimid?) (p)kringle

L5 126 (SUCCINIMIDYL OR MALEIMID?) (P) KRINGLE

-> s 15 (p) (coupl? or conjug?)

L6 114 L5 (P) (COUPL? OR CONJUG?)

-> dup remo l6

PROCESSING COMPLETED FOR L6

L7 110 DUP REMO L6 (4 DUPLICATES REMOVED)

-> s l7 and kringle(p)5

L8 109 L7 AND KRINGLE(P) 5

-> s 18 and albumin

L9 76 L8 AND ALBUMIN

-> dup remo l9

PROCESSING COMPLETED FOR L9

L10 76 DUP REMO L9 (0 DUPLICATES REMOVED)

-> d l10 70-76 bib abs

L10 ANSWER 70 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 1996038557 PCTFULL ED 20020514

T1EN HEPATOCYTE GROWTH FACTOR RECEPTOR ANTAGONISTS AND USES THEREOF

T1FR ANTAGONISTES DU RECEPTEUR DU FACTEUR DE CROISSANCE DES HEPATOCYTES ET

LEURS UTILISATIONS

SCHWALL, Ralph, H.;

TABOR, Kelly, Helen

GENENTECH, INC.;

SCHWALL, Ralph, H.;

TABOR, Kelly, Helen

English

Patent

WO 9638557

W:

AI 19961205

AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB

GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MK MN MW

UX VN KE LS NM SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT BE

CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG

CI CM CA GN ML MR NE SN TD TG

WO 1996-US8094

US 1995-8/460.368

PRAI 19950602

ABEN Hepatocyte growth factor (HGF) receptor antagonists are provided. The

HGF receptor antagonists

include HGF receptor antibodies and fragments thereof. The HGF receptor

antagonists can be employed

to block binding of HGF to HGF receptors or substantially inhibit HGF

receptor activation. The HGF

receptor antagonists may be included in pharmaceutical compositions,

articles of manufacture, or

kits. Methods of treating cancer using the HGF receptor antagonists are

also provided.

L'invention concerne des antagonistes du recepteur de croissance des

hepatocytes (HGF), qui

comportent des anticorps contre le recepteur HGF et des fragments de

ceux-ci. Lesdits antagonistes

du recepteur de HGF peuvent etre utilises pour bloquer la liaison du HGF

aux recepteurs de HGF ou

pour inhiber sensiblement l'activation du recepteur de HGF. Les

antagonistes de HGF peuvent etre

integres dans des compositions pharmaceutiques, des articles

manufactures ou des trousseaux.

L'invention porte egalement sur des methodes de traitement du cancer au

moyen desdits antagonistes

du recepteur de HGF.

ANSWER 71 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN

AN 1996015244 PCTFULL ED 20020514

T1EN SENSORY AND MOTOR NEURON DERIVED FACTOR (SMDF)

T1FR FACTEUR DERIVE DES NEURONES SENSORIELS ET MOTEURS (SMDF)

IN HO, Wei-Hsien;

OSHEROFF, Phyllis, L.

GENENTECH, INC.;

HO, Wei-Hsien;

OSHEROFF, Phyllis, L.

English

Patent

WO 9615244

W:

A2 19960523

CA JP MX US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT

SE

AI 1995-US14575

US 1994-8/339,517

PRAI 19941114

ABEN Isolated SMDF, isolated DNA encoding SMDF, and recombinant or synthetic

methods of preparing

SMDF are disclosed. SMDF contains a 'beta'-type EGF-like domain and a

N-terminal sequence which is

distinct from all neuregulins reported so far. SMDF, when expressed in

recombinant cell culture,

activates tyrosine phosphorylation of the HER2/neu receptor in human

breast cancer cells and

displays mitogenic activity on Schwann cells. Northern blot and in situ

hybridization analysis show

that SMDF differs from other neuregulins in that it is nervous tissue

specific, and is very highly

US 5826292  
US 207520  
6068522

ABFR

expressed, in comparison to other neuroregulins, in the human and rat spinal cord motor neurons and sensory neurons.

L'invention concerne le SMDF isole, un ADN Isolé codant pour le SMDF, et des procedes synthetiques ou de recombinaison pour preparer ce facteur. Ce dernier contient un domaine proche du facteur de croissance de l'epithelium du type 'beta' et une sequence N-terminale qui est distincte de toutes les neuroregulines decrites jusqu'a present. Lorsqu'il est exprime en culture cellulaire recombinee, le SMDF active la phosphorylation de la tyrosine du recepteur HER2/new dans les cellules humaines du cancer du sein et presente une activite mitogene sur les cellules de Schwann. Une analyse northern blot et par hybridation in situ revele que le SMDF differe des autres neuroregulines en ce qu'il est specifique des tissus nerveux, et est tres fortement exprime, par rapport aux autres neuroregulines, dans les neurones moteurs et les neurones sensoriels de la moelle epiniere de l'homme et du rat.

ANSWER 72 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STVN  
1996004004 PCTFULL ED 20020514  
COMPOSITIONS AND METHODS FOR THE DELIVERY OF DRUGS BY PLATELETS FOR THE  
TREATMENT OF CARDIOVASCULAR DISEASES  
COMPOSITIONS ET PROCÉDES D'APPORT DE MÉDICAMENTS PAR LES PLAQUETTES POUR  
LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES  
GUREWICH, Victor  
NEW ENGLAND DEACONESS HOSPITAL CORPORATION  
English  
Patent  
WO 9604004 AI 19960215  
W: AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE  
WO 1995-US9848 A 19950803  
US 1994-8/7286,748 19940805  
A fusion drug including an isolated portion of the A-chain of a

urokinase-type plasminogen activator linked to a drug, wherein the A-chain portion binds stably to an outer membrane of a platelet. The figure shows the primary sequence of urokinase, including the A-chain. The half-life of the fusion drug in plasma is thereby increased to about 4 to 5 days, and the fusion drug is automatically targeted to forming thrombi and sites of vascular injury. The fusion drug can thus be used to treat cardiovascular diseases, e.g., as adjunctive therapy to inhibit reclosures in a patient after thrombolytic therapy or angioplasty. Médicament de fusion comprenant une partie isolée de la chaîne A d'un activateur de urokinase.

plasminogène de type urokinase liée à un médicament, la partie de chaîne A formant une liaison stable avec une membrane extérieure de plaquette. La figure illustre la séquence primaire d'urokinase, y compris la chaîne A. La demi-vie du médicament de fusion dans le plasma est, de ce fait, prolongée de 4 à 5 jours et le médicament de fusion est cible automatiquement vers le thrombus en formation et vers les sites de lésion vasculaire. On peut ainsi utiliser le médicament de fusion, afin de traiter des maladies cardio-vasculaires, par exemple, en tant que thérapie d'appoint servant à inhiber des reocclusions chez un patient après une thérapie thrombolytique ou une angioplastie.

L10 ANSWER '73 OF '76 PCTFULL COPYRIGHT 2006 Univeritio on STN  
AN 1994006456 PCTFULL ED 20020513

TIEN  
TIFR  
IN  
PA  
LA  
DT  
PI  
DS  
AI  
PRAI  
ABEN  
ABER

L10  
AN  
TIEN  
TIFR  
IN

PA  
LA  
DT  
PI  
DS  
  
AI  
PRAI  
ABEN

**ABFR**

LL10  
AN  
TIEN  
TIFR  
IN  
PA

PROTECTION AGAINST LIVER DAMAGE BY HGF  
PROTECTION CONTRE DES LESIONS HEPATIQUES AU MOYEN DU FACTEUR DE CROISSANCE D'HEPATOCYTES (HGF)

WOOS, Philip;  
SCHWALL, Ralph  
GENENTECH, INC.;  
WOOS, Philip;  
SCHWALL, Ralph  
English Patent

AL 19940331  
CA JP US AT BE CH DE DK ES FR GB IE IT LU MC NL PT SE  
A 1930915 A  
US 1992-7/946,263  
US 1992-7/988,711  
19921030

The invention concerns the use of HGF in the prevention of the establishment or of the progress of liver damage in patients at risk of developing or having been diagnosed with liver damage.  
L'invention se rapporte à l'utilisation d'HGF pour la prévention de la apparition ou le développement des lésions hépatiques chez des patients présentant le risque de développer de telles lésions ou chez lesquels de telles lésions ont été diagnostiquées.

ANSWER 74 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN  
1999400594 PCTFULL ED 20020513  
METHODS FOR USING CKS FUSION PROTEINS  
D'UTILISATION DES PROTEINES DE FUSION CKS  
ROLLING, Timothy, J.;  
MANECKI, Wlodzimierz;  
DEDEVARE, Sushil, G.;  
CASEY, James, M.;  
DESAI, Suresh, M.  
ABBOTT LABORATORIES  
English  
Patent  
MO 9400594  
W:  
AU CA JP KR AT BE CH DE DK ES FR GB IE IT LU MC NL PT  
SE

MO 1993-US5924 A 19930621  
US 1992-7/903 043 19920623

Improved methods for detecting antibodies in test samples. The improvement comprises uses of specific antibodies for the antibodies in assays such as CKS-fusion proteins specific for the antibodies in assays such as screening assays, competitive assays, confirmatory assays and immunodot assays. Test kits which contain these CKS-fusion proteins are also provided.

L'invention concerne des procedes perfectionnes de detection d'anticorps dans des echantillons d'essai. L'amelioration consiste a utiliser les proteines de fusion CKS specifiques aux anticorps dans des tests tels que les analyses de depistage, les dosages par radiocompetition, les dosages de competition et les dosages immunologiques par point. Des kits d'analyse contenant ces proteines de fusion CKS utilisent dans ledits tests sont egalement decrits.

ANSWER 75 OF 76 PCTFULL COPYRIGHT 2006 Univerisio on STN  
ED 20020513  
HEPATOCYTES GROWTH FACTOR VARIANTS  
DU FACTION DE CROISSANCE DES HEPATOCYTES  
SODOWSKI, Paul, J.;  
LOKKER, Nathalie, A.;  
MARK, Melanie, R.;  
GENENTECH, INC.;  
SODOWSKI, Paul, J.;  
LOKKER, Nathalie, A.;



aminophospholipides, ainsi que des  
procedes servant a administrer de facon specifique des agents  
therapeutiques, y compris des toxines  
et des coagulants, aux aminophospholipides d'expression stable de  
vaisseaux sanguins tumoraux, ce  
qui provoque une thrombose, une necrose et une regression de la tumeur.

ANSWER 61 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN  
2000002584 PCTFULL ED 20020515  
TIFR CANCER TREATMENT METHODS USING ANTIBODIES TO AMINOPHOSPHOLIPIDS  
IN PROCESSES DE TRAITEMENT DU CANCER REPOSANT SUR L'UTILISATION D'ANTICORPS  
VIS-A-VIS DES AMINOPHOSPHOLIPIDES  
THORPE, Philip, E.;

PA RAN, Sophia  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
LA English  
DT Patent  
PI Patent  
DS WO 2000002584

W: A2 20000120  
AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE  
ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ  
LC LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU  
SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GM  
KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE  
CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF  
CG CI CM GN GW ML MR NE SN TD TG

AI WO 1999-US15600  
PRAI US 1998-60/092,672 19980712  
US 1998-60/110,608 19981202  
ABEN Disclosed are the surprising discoveries that aminophospholipids, such  
as phosphatidylserine  
and phosphatidylethanolamine, are stable and specific markers accessible  
on the luminal surface of  
tumor blood vessels, and that the administration of an  
anti-aminophospholipid antibody alone is  
sufficient to induce thrombosis, tumor necrosis and tumor regression  
(in vivo). This invention  
therefore provides anti-aminophospholipid antibody-based methods and  
compositions for use in the  
specific destruction of tumor blood vessels and in the treatment of  
solid tumors. Although various  
antibody conjugates and combinations are thus provided, the use of  
naked, or unconjugated,  
anti-phosphatidylserine antibodies is a particularly important aspect of  
the invention, due to  
simplicity and effectiveness of the approach.

ABFR L'invention concerne la decouverte surprenante selon laquelle les  
aminophospholipides, du type  
phosphatidylserine et phosphatidylethanolamine, sont des marqueurs  
stables et accessibles a la  
surface intracavitare des vaisseaux sanguins de tumeur, et selon  
laquelle la simple administration  
d'anticorps vis-a-vis des aminophospholipides suffit a induire la  
thrombose, la necrose tumorale et  
la regression tumorale (in vivo). En consequence, l'invention concerne  
des procedes reposant sur  
l'utilisation d'anticorps vis-a-vis des aminophospholipides, et des  
compositions destinees a etre  
utilisees pour la destruction specifique des vaisseaux sanguins de  
tumeur et le traitement des  
tumeurs solides. Bien que l'invention concerne ainsi plusieurs conjugues  
et combinaisons  
d'anticorps, l'utilisation d'anticorps nus ou non conjugues vis-a-vis du  
type phosphatidylserine est  
un aspect particulierement important de l'invention, grace a la  
simplicite et a l'efficacite de  
l'approche consideree

L10 ANSWER 62 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN  
AN 1999046281 PCTFULL ED 20020515

TIFR NOVEL POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME  
IN NOUVEAUX POLYPEPTIDES ET ACIDES NUCLEIQUES LES CODANT

PA WOOD, William, I. ;  
GODDARD, Audrey ;  
GURNEY, Austin ;  
YUAN, Jean ;  
CHEN, Kevin, P. ;  
GENENTECH, INC. ;  
WOOD, William, I. ;  
GODDARD, Audrey ;  
GURNEY, Austin ;  
YUAN, Jean ;  
BAKER, Kevin, P. ;  
CHEN, Jian

LA English  
DT Patent  
PI Patent  
DS WO 9946281

W: A2 19990916  
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC  
LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD  
SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW GM  
KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH  
CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG  
CI CM GN GW ML MR NE SN TD TG

AI WO 1999-US028  
PRAI US 1998-60/077,450  
US 1998-60/077,450 19980310  
US 1998-60/077,632 19980311  
US 1998-60/077,641 19980311  
US 1998-60/077,649 19980312  
US 1998-60/077,791 19980312  
US 1998-60/078,004 19980313  
US 1998-09/040,220 19980317  
US 1998-60/078,886 19980320  
US 1998-60/078,910 19980320  
US 1998-60/078,939 19980320  
US 1998-60/078,936 19980320  
US 1998-60/079,294 19980325  
US 1998-60/078,656 19980326  
US 1998-60/079,728 19980327  
US 1998-60/079,786 19980327  
US 1998-60/079,664 19980327  
US 1998-60/079,689 19980327  
US 1998-60/079,663 19980327  
US 1998-60/079,923 19980330  
US 1998-60/079,920 19980330  
US 1998-60/080,105 19980331  
US 1998-60/080,165 19980331  
US 1998-60/080,194 19980331  
US 1998-60/080,107 19980331  
US 1998-60/080,333 19980401  
US 1998-60/080,327 19980401  
US 1998-60/080,334 19980401  
US 1998-60/080,328 19980401  
US 1998-60/081,071 19980408  
US 1998-60/081,070 19980408  
US 1998-60/081,049 19980408  
US 1998-60/081,195 19980409  
US 1998-60/081,203 19980409  
US 1998-60/081,229 19980409  
US 1998-60/081,838 19980415  
US 1998-60/081,955 19980415  
US 1998-60/081,952 19980415  
US 1998-60/081,817 19980421  
US 1998-60/082,569 19980421  
US 1998-60/082,568 19980421  
US 1998-60/082,700 19980422  
US 1998-60/082,804 19980422  
US 1998-60/082,704 19980422

[illegible]





PLAN BIOLOGIQUE ET CONTENANT DES LIAISONS DISULFURE, A L'INTERIEUR DE CELLULES BACTERIENNES

IN GEORGIOU, George;  
OSTERMEIER, Marc  
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM  
English  
Patent  
PI WO 9738123  
DS

AL 19971016  
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU  
LV MD MG MK MN MW MX NZ PZ RO RU SD SE SG SI SK TJ  
TM TR TT UA UG UZ VN YU YE ZS ZZ  
KZ MD RU TJ TM AT BE DE DK ES FI FR GB GR IE IT LU MC  
NL PT SE BF BJ CF CG CI CM CN GN ML MR NE SN TD TG

WO 1997-05636  
US 1996-60/014,950 A 19960405  
Disclosed are methods of producing eukaryotic disulfide bond-containing polypeptides in bacterial hosts, and compositions resulting therefrom. Co-expression of a eukaryotic foldase and a disulfide bond-containing polypeptide in a bacterial host cell is demonstrated. In particular, the methods have been used to produce mammalian pancreatic trypsin inhibitor and tissue plasminogen activator (tPA) in soluble, biologically-active forms, which are isolatable from the bacterial periplasm. Also disclosed are expression systems, recombinant vectors, and transformed host cells.

Cette invention concerne des procedes de production de polypeptides eucaryotes, solubles, qui sont actifs sur plan biologique et qui contiennent des liaisons disulfure, ceci a l'interieur d'hotes bacteriens. Cette invention, qui concerne egalement les compositions ainsi obtenues, a permis de demontrer la co-expression d'une foldase eucaryote et d'un polypeptide contenant une liaison disulfure a l'interieur d'une cellule bacterienne hote. Dans des modes de realisation particuliers, ces procedes ont permis de produire un inhibiteur de trypsiine pancreatique chez les mammiferes ainsi qu'un activateur plasminogene de tissus (tPA), lesquels se presentent sous des formes solubles, actives sur le plan biologique, et pouvant etre isolees du periplasme bacterien. Cette invention concerne enfin des systemes d'expression, des vecteurs recombinants, ainsi que des cellules hotes transformees.

ANSWER 68 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN  
AN 1997035885 PCTFULL ED 20020514  
TIEN ERBB3 ANTIBODIES  
TIFR ANTICORPS DE LA PROTEINE ERBB3  
IN AKITA, Robert;  
SLIWOMSKI, Mark  
GENENTECH, INC.  
English  
LA Patent  
DT WO 9735885  
PI  
DS

AL 19971002  
AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES  
FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LV  
MD MG MK MN MW MX NZ PZ RO RU SD SE SG SI SK TJ TM  
TR TT UA UG UZ VN YU YE ZS ZZ  
RU TJ TM AT BE DE DK ES FI FR GB GR IE IT LU MC NL PT  
SE BF BJ CF CG CI CM CN GN ML MR NE SN TD TG

WO 1997-053546  
US 1996-8/624,036 A 19960327  
Antibodies are disclosed which bind to Erbb3 protein and further possess any one or more of the

following properties: an ability to reduce heregulin-induced formation of an Erbb2-ErbB3 protein complex in a cell which expresses Erbb2 and Erbb3; the ability to increase the binding affinity of heregulin for Erbb3 protein; and the characteristic of reducing heregulin-induced Erbb2 activation in a cell which expresses Erbb2 and Erbb3.

L'invention a trait a des anticorps se fixant a la proteine Erbb3 et qui possedent, en outre, l'une des proprietes suivantes ou avantage: aptitude a reduire la formation, induite par l'hereguline, d'un complexe proteique Erbb2-ErbB3 dans une cellule qui exprime les proteines Erbb2 et Erbb3; aptitude a accroitre l'affinite de fixation de l'hereguline pour la proteine Erbb3 et pour la proteine Erbb2 et Erbb3; aptitude a reduire l'activation de la proteine Erbb2 induite par l'hereguline dans une cellule qui exprime les proteines Erbb2 et Erbb3.

ANSWER 69 OF 76 PCTFULL COPYRIGHT 2006 Univentio on STN  
AN 1997017371 PCTFULL ED 20020514  
TIEN ISOLATION OF apo(a), COMPOSITIONS, AND METHODS OF USE  
TIFR ISOLATION OF L'apo(a), COMPOSITIONS ET PROCESSES D'UTILISATION  
IN SCANU, Angelo, M.;  
EDELSTEIN, Celina  
ARCH DEVELOPMENT CORPORATION  
English  
LA Patent  
DT WO 9717371  
PI  
DS

AL 19970515  
AL AM AT AU BA BB BG CA CH CN CU CZ DE DK EE ES FI GB GE  
HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK  
MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA  
UG UZ VN KE LS MW SD SZ UG AM AZ BY KG KZ MD RU TJ TM AT  
BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF  
CG CI CM GN ML MR NE SN TD TG

WO 1996-US18136 A 19961108  
US 1995-60/006,395 19951109  
US 1996-8/691,795 19960802  
Disclosed are novel compositions comprising purification of active apolipoprotein (a), apo(a), derived from Lp(a). Also disclosed are methods for determining elastase activity and methods for screening for inhibitors of elastase activity. Methods are also disclosed for purifying, quantitating, and reconstituting active lipoprotein(a), Lp(a). On obtient de nouvelles compositions impliquant la purification de l'apolipoproteine (a), apo(a), derivee de Lp(a). On decrit des procedes permettant de determiner l'activite elastase, et des procedes de criblage d'inhibiteurs de l'activite elastase. On decrit enfin des procedes de purification, quantification et reconstitution de lipoproteine (a) active, Lp(a).

(FILE 'HOME' ENTERED AT 19:33:22 ON 02 APR 2006)

FILE 'CAPLUS, USPATFULL, USPAT2, PCTFULL, BIOSIS, SCISEARCH, MEDLINE' ENTERED AT 19:34:20 ON 02 APR 2006

L1 11704 S SUCCINIMIDYL AND MALEIMID?  
L2 11039 S L1 AND (COUPL? OR CONJUG?)  
L3 405 S L2 AND KRINGLE  
L4 377 DUP REMO L3 (28 DUPLICATES REMOVED)  
L5 126 S (SUCCINIMIDYL OR MALEIMID?) (P)KRINGLE  
L6 114 S L5 (P) (COUPL? OR CONJUG?)  
L7 110 DUP REMO L6 (4 DUPLICATES REMOVED)  
L8 109 S L7 AND KRINGLE (P) 5

=> d his

L19 76 S L8 AND ALBUMIN  
 L10 76 DUP REMO L9 (0 DUPLICATES REMOVED)  
 => b medline biosis scisearch  
 COST IN U.S. DOLLARS  
 FULL ESTIMATED COST  
 FILE 'MEDLINE' ENTERED AT 19:39:45 ON 02 APR 2006  
 FILE 'BIOSIS' ENTERED AT 19:39:45 ON 02 APR 2006  
 Copyright (c) 2006 The Thomson Corporation  
 FILE 'SCISEARCH' ENTERED AT 19:39:45 ON 02 APR 2006  
 Copyright (c) 2006 The Thomson Corporation  
 => s l10  
 L11 0 L10  
 => s l8  
 L12 0 L8  
 => s l6  
 L13 3 L6  
 => dup remo l13  
 PROCESSING COMPLETED FOR L13  
 L14 1 DUP REMO L13 (2 DUPLICATES REMOVED)  
 => d l14 bib abs  
 L14 ANSWER 1 OF 1 MEDLINE on STN DUPLICATE 1  
 AN 2004122095  
 DN PubMed ID: 15012978  
 TI Kringle 5 peptide-albumin conjugates with anti-migratory activity.  
 AU Leger Roger; Benquet Corinne; Huang Xicai; Quraishi Omar; van Wyk Pieter;  
 Bridon Dominique  
 CS Research Department, ConjuChem Inc., 225 President-Kennedy Ave., Suite  
 3950, Montreal, QC, H2X 3Y8 Canada. leger@conjuchem.com  
 SO Bioorganic & medicinal chemistry letters, (2004 Feb 23) Vol. 14, No. 4,  
 pp. 841-5.  
 Journal code: 9107377. ISSN: 0960-894X.  
 England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200409  
 ED Entered STN: 20040312  
 Last Updated on STN: 20040929  
 Entered Medline: 20040928  
 AB Three peptide fragments of the kringle 5 region of plasminogen  
 and their respective N- and C-terminus maleimido derivatives  
 conjugated to Cy34 of human serum albumin were evaluated in vitro  
 using a human umbilical vein endothelial cell (HUVEC) migration assay and  
 a human plasma stability assay. The N-terminus maleimido  
 derivative of the 64 to 74 segment of kringle 5  
 conjugated to human serum albumin possessed remarkable  
 anti-migratory activity.

=>